Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

被引：2

作者：

Kurzrock, Razelle ^{[1
]}

Voorhees, Peter M. ^{[2
]}

Casper, Corey ^{[3
]}

Furman, Richard R. ^{[4
]}

Fayad, Luis ^{[1
]}

Lonial, Sagar ^{[5
]}

Borghaei, Hossein ^{[6
]}

Jagannath, Sundar ^{[7
]}

Sokol, Lubomir ^{[8
]}

Usmani, Saad ^{[9
]}

van de Velde, Helgi ^{[10
]}

Qin, Xiang ^{[11
]}

Qi, Ming ^{[11
]}

Cornfeld, Mark J. ^{[12
]}

van Rhee, Frits ^{[13
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[4] Cornell Univ, Weill Med Coll, New York, NY 10021 USA

[5] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[7] St Vincents Comprehens Canc Ctr, New York, NY USA

[8] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[9] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

[10] Janssen Res & Dev, Beerse, Belgium

[11] Ortho Biotech Oncol Res & Dev, Malvern, PA USA

[12] Ortho Biotech Oncol Res & Dev, Raritan, NJ USA

[13] Bon Secours St Francis Hlth Syst, Hematol Oncol, Greenville, SC USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

10.1182/blood.V118.21.3959.3959

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页码：1693 / 1693

页数：1

共 50 条

[1] Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Xie, Lanyi
Li, Lilian Y.
Kurzrock, Razelle
van Rhee, Frits
Qin, Xiang
Reddy, Manjula
Qi, Ming
Davis, Hugh M.
Zhou, Honghui
Puchalski, Thomas A.
BLOOD, 2012, 120 (21)
[2] A Phase I Study of CNTO 328, An Anti-Interelukin-6 Monoclonal Antibody in Patients with A-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.
Kurzrock, Razelle
Fayad, Luis
Voorhees, Peter
Furman, Richard R.
Lonial, Sagar
Borghaei, Hossein
Jagannath, Sundar
Sokol, Lubomir
Cornfeld, Mark
Qi, Ming
Jiao, Trina
Herring, Jennifer
Qin, Xiang
van Rhee, Frits
BLOOD, 2008, 112 (11) : 371 - 372
[3] A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Kurzrock, Razelle
Voorhees, Peter M.
Casper, Corey
Furman, Richard R.
Fayad, Luis
Lonial, Sagar
Borghaei, Hossein
Jagannath, Sundar
Sokol, Lubomir
Usmani, Saad Z.
de Velde, Helgi van
Qin, Xiang
Puchalski, Thomas A.
Hall, Brett
Reddy, Manjula
Qi, Ming
van Rhee, Frits
CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3659 - 3670
[4] An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman's Disease
Van Rhee, Frits
Casper, Corey
Voorhees, Peter M.
Fayad, Luis E.
van de Velde, Helgi
Vermeulen, Jessica
Qin, Xiang
Qi, Ming
Tromp, Brenda
Kurzrock, Razelle
BLOOD, 2013, 122 (21)
[5] A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
Rossi, J-F
Negrier, S.
James, N. D.
Kocak, I.
Hawkins, R.
Davis, H.
Prabhakar, U.
Qin, X.
Mulders, P.
Berns, B.
BRITISH JOURNAL OF CANCER, 2010, 103 (08) : 1154 - 1162
[6] A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
J-F Rossi
S Négrier
N D James
I Kocak
R Hawkins
H Davis
U Prabhakar
X Qin
P Mulders
B Berns
British Journal of Cancer, 2010, 103 : 1154 - 1162
[7] A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
van Rhee, Frits
Casper, Corey
Voorhees, Peter M.
Fayad, Luis E.
de Velde, Helgi van
Vermeulen, Jessica
Qin, Xiang
Qi, Ming
Tromp, Brenda
Kurzrock, Razelle
ONCOTARGET, 2015, 6 (30) : 30408 - 30419
[8] A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
Voorhees, Peter M.
Manges, Robert F.
Sonneveld, Pieter
Jagannath, Sundar
Somlo, George
Krishnan, Amrita
Lentzsch, Suzanne
Frank, Richard C.
Zweegman, Sonja
Wijermans, Pierre W.
Orlowski, Robert Z.
Kranenburg, Britte
Hall, Brett
Casneuf, Tineke
Qin, Xiang
van de Velde, Helgi
Xie, Hong
Thomas, Sheeba K.
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (03) : 357 - 366
[9] The long-term safety and efficacy of hunanized anti-interleukin-6 receptor monoclonal antibody, MRA in multicentri Castleman's disease.
Nishimoto, N
Kanakura, Y
Aozasa, K
Johkoh, T
Nakamura, M
Nakano, S
Nakano, N
Ikeda, Y
Sasaki, T
Nishioka, K
Hara, M
Taguchi, H
Kimura, Y
Kato, Y
Asaoku, H
Kodama, F
Yoshizaki, K
Kishimoto, T
BLOOD, 2003, 102 (11) : 646A - 647A
[10] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman's Disease
Wong, Raymond S.
Casper, Corey
Munshi, Nikhil
Ke, Xiaoyan
Fossa, Alexander
Simpson, David
Capra, Marcelo
Liu, Ting
Hsieh, Ruey Kuen
Goh, Yeow Tee
Zhu, Jun
Cho, Seok-Goo
Ren, Hanyun
Cavet, James
Bandekar, Rajesh
Rothman, Margaret
Puchalski, Thomas A.
Chaturvedi, Shalini
de Velde, Helgi van
Vermeulen, Jessica
van Rhee, Frits
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →